Harley-Davidson to recall more than 65,000 motorcycles to fix rear shock absorbers
Shares of Harley-Davidson Inc. (HOG) dropped 1.9% in morning trading Tuesday, in the wake of the motorcycle maker's recall of more than 65,000 motorcycles to fix rear shock absorbers. "A fastener securing the rear shock absorber may break and allow the rear shock absorber adjuster to damage the rear tire, causing a loss of tire pressure," according to a notice from the U.S. National Highway Traffic Safety Administration. "A loss of tire pressure can lead to a loss of vehicle control, increasing the risk of a crash." The recall is for certain 2018 to 2019 FLDE, 2018-2021 FLHC, 2018 to 2023 FLHCS, 2018 and 2023 FLHCS ANV, 2020 to 2023 FXLRS, 2022 to 2023 FXLRST and 2022 FXRST Softail motorcycles. The stock has dropped 19.3% year to date, while the S&P 500 has climbed 17.3%.
-Tomi Kilgore
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-05-23 0940ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track